Concepedia

Author

C. Seynaeve

Leiden University Medical Center

Also Known As

C SEYNAEVE, C Seynaeve, C. Seynaeve, Caroline Seynaeve, J. L. de Lange, Ondansetron Study Group, S. Tchatchou

71

Publications

1.7K

Citations

19

H-Index

41

Concepts

All Affiliations

Leiden University Medical CenterRotterdam University of Applied SciencesErasmus University RotterdamErasmus MCUniversity Medical Center Utrecht
CS

About

C. Seynaeve is an author at Leiden University Medical Center specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

14

508

2

Health Sciences

3

3

74

3

Cell Biology

1

1

11

4

Child Development

1

1

52

5

Family Medicine

1

1

52

C. Seynaeve

×

18

Publications

1.4K

Citations

16

H-Index

YearCitations

Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

Xiaohong R. Yang, Jenny Chang‐Claude, Ellen L. Goode,

JNCI Journal of the National Cancer Institute

2010

711

Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study

Iris van Oostrom, Hanne Meijers‐Heijboer, H.J. Duivenvoorden,

Clinical Genetics

2006

74

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

Carolien H. Smorenburg, M. Bontenbal, C. Seynaeve,

Breast Cancer Research and Treatment

2001

73

Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.

SE Jones, C. Seynaeve, Annette Hasenburg,

Cancer Research

2009

63

Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing

Iris van Oostrom, Hanne Meijers-Heijboer, H.J. Duivenvoorden,

Annals of Oncology

2006

52

A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours

Jean‐Yves Blay, Axel Le Cesne, Jaap Verweij,

European Journal of Cancer

2004

51

Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.

Daniel Rea, Annette Hasenburg, C. Seynaeve,

Cancer Research

2009

44

Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin

Astrid W. Oosten, C. Seynaeve, P.I.M. Schmitz,

Sarcoma

2009

44

Relevant impact of central pathology review on nodal classification in individual breast cancer patients

J.H.M.J. Vestjens, Manon J. Pepels, Maaike de Boer,

Annals of Oncology

2012

43

Randomized Phase II Study of Docetaxel versus Doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Jaap Verweij, S.M. Lee, W. Ruka,

UCL Discovery (University College London)

2000

36

Page 1